The tweet was deleted by the author.
But we saved everything 🙂.
Patrick Soon-Shiong, a notable entrepreneur and biotech expert, has shared significant news regarding the treatment of pancreatic cancer. After two decades since the initial approval of Abraxane for pancreatic cancer, a new randomized trial reveals promising results. The combination of Abraxane and Gemcitabine has now been demonstrated to result in significantly longer overall survival for patients with this challenging disease, especially when compared to traditional toxic combination therapies.
This development marks a pivotal moment in cancer treatment, offering a new potential standard for patients suffering from pancreatic cancer. The findings could lead to a shift in how this aggressive cancer type is treated, providing hope for improved patient outcomes.
These findings further underscore Patrick Soon-Shiong’s ongoing commitment to innovative cancer therapies, building on his previous examination of the link between COVID-19 and increased throat cancer risk and his coverage of successful outcomes in HPV cancer Bioshield trials. As the landscape of oncology continues to evolve, such advancements reflect a broader pattern in Soon-Shiong’s work of highlighting breakthroughs at the intersection of medicine and patient care.